3 research outputs found
Extracellular Vesicles as Potential Tools for Regenerative Therapy
[Abstract]
Small extracellular vesicles released by fibroblasts from young human donors diminish lipid peroxidation
in senescent cells and in different old mice organs due to their enrichment in Glutathione-S-transferase
Mu lipid antioxidant activity.The London School of Medicine and Dentistry; MGU0497Biotechnology and Biological Sciences Research Council; BB/P000223/1Instituto de Salud Carlos III; CP19-0010Ministerio de Economía, Industria y Competitividad; SAF2016-78666RXunta de Galicia; ED481B 2017/11
MYH10 activation rescues contractile defects in arrhythmogenic cardiomyopathy (ACM).
The most prevalent genetic form of inherited arrhythmogenic cardiomyopathy (ACM) is caused by mutations in desmosomal plakophilin-2 (PKP2). By studying pathogenic deletion mutations in the desmosomal protein PKP2, here we identify a general mechanism by which PKP2 delocalization restricts actomyosin network organization and cardiac sarcomeric contraction in this untreatable disease. Computational modeling of PKP2 variants reveals that the carboxy-terminal (CT) domain is required for N-terminal domain stabilization, which determines PKP2 cortical localization and function. In mutant PKP2 cells the expression of the interacting protein MYH10 rescues actomyosin disorganization. Conversely, dominant-negative MYH10 mutant expression mimics the pathogenic CT-deletion PKP2 mutant causing actin network abnormalities and right ventricle systolic dysfunction. A chemical activator of non-muscle myosins, 4-hydroxyacetophenone (4-HAP), also restores normal contractility. Our findings demonstrate that activation of MYH10 corrects the deleterious effect of PKP2 mutant over systolic cardiac contraction, with potential implications for ACM therapy.This study was supported by MCIU grant BFU2016-75144-R and PID2020-
116935RB-I00, and by a “la Caixa” Banking Foundation grant under the
project code HR18-00304” to J.A.B.; The study was also supported by
the “Ayudas a la Investigación Cátedra Real Madrid-Universidad Europea” (2017/RM01). C.M.-L. and S.S. hold MCIU predoctoral contracts
BES-2017-079715, and BES-2017-079707 respectively. R.G. acknowledges funding from the European Research Council under grant ERCAG-340177 (3DNanoMech) and from the MCIU under grant MAT2016-
76507-R. The CNIC is supported by the Instituto de Salud Carlos III
(ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC
Foundation and is a Severo Ochoa Center of Excellence, grant
CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033. The
microscopy experiments were carried out at the Dynamic Microscopy
and Image Unit, CNIC, ICTS-ReDib, co-financed by MCIN/AEI /10.13039/
501100011033 and FEDER “A way of making Europe” (#ICTS-2018-04-
CNIC-16). Imaris full analysis were carried out at the Microscopy &
Dynamic Imaging, CNIC, ICTS-ReDib, co-funded by MCIN/AEI
/10.13039/501100011033. Biomedical Imaging has been conducted at
the Advanced Imaging Unit of the CNIC (Centro Nacional de Investigaciones Cardiovasculares Carlos III), Madrid, Spain. This project used the
ReDIB ICTS infrastructure TRIMA@CNIC, Ministerio de Ciencia e Innovación (MCIN).S
Recommended from our members
An aphasia research agenda - a consensus statement from the collaboration of aphasia trialists.
Coordination of international aphasia research would minimise duplication of effort, support synergistic international activities across languages and multidisciplinary perspectives, and promote high-quality conduct and reporting of aphasia research, thereby increasing the relevance, transparency, and implementation of findings. The Collaboration of Aphasia Trialists (CATs) sought to develop an aphasia research agenda to direct future research activities, based on priorities shared by people with aphasia, family members, and healthcare professionals. Our established international research network spanning 33 countries contributed to this activity. Research literature reporting the priorities of stakeholders was reviewed and synthesised (phase 1). Representatives from Working Groups on Aphasia Assessment & Outcomes, Prognosis & Predictors of Recovery, Effectiveness of Interventions, and Societal Impact & Reintegration participated in a two-day research agenda setting meeting. The CATs expert panel refined research objectives and identified constituent components of research and methodological developments required to address these research components. The objectives and research components were grouped into overarching themes (phase 2). The resultant list was then circulated to more than 180 CATs members for review, revision, and approval. Consensus on the final aphasia research agenda and road-map was reached by CATs executive committee (phase 3). The expert panel identified five overarching research themes: (i) evidence-based interventions for people with aphasia, (ii) effective interventions to support those communicating with people with aphasia, (iii) cross-linguistic assessment and core outcomes for aphasia research, (iv) predictors of language recovery, and (v) clinical implementation of research findings. Within these broad themes, 30 research objectives and 91 individual aphasia research components were identified and sequentially ordered. This agenda builds on research priorities identified by people with aphasia and their families, and includes priorities of healthcare professionals and researchers, and will support the rehabilitation and recovery of people with aphasia. Our internationally relevant research agenda promotes rigour in methodology, considers international applicability, synergistic activities, and sharing of resources and expertise